Shopping Cart
Remove All
Your shopping cart is currently empty
Indatuximab ravtansine
😃Good
Catalog No. T9901A-224Cas No. 1238517-16-2
Alias nBT062-DM4, BT-062
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) that consists of a murine-human chimeric form based on B-B4, which specifically targets CD138, linked via a disulfide bond to the maytansinoid drug DM4. It exhibits antitumor activity.
Indatuximab ravtansine
Indatuximab ravtansine
😃Good
Catalog No. T9901A-224Alias nBT062-DM4, BT-062Cas No. 1238517-16-2
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) that consists of a murine-human chimeric form based on B-B4, which specifically targets CD138, linked via a disulfide bond to the maytansinoid drug DM4. It exhibits antitumor activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) that consists of a murine-human chimeric form based on B-B4, which specifically targets CD138, linked via a disulfide bond to the maytansinoid drug DM4. It exhibits antitumor activity. |
| In vitro | Indatuximab ravtansine demonstrated cytotoxic effects in RPMI 8226, MOLP-8, and U266 cell lines (with significant CD138 expression) at concentrations ranging from 1 pM to 100 nM over five days. The IC50 values for RPMI 8226, MOLP-8, and U266 were 200 pM, 40 pM, and 20 pM, respectively. |
| In vivo | Indatuximab ravtansine (5.3-21.2 mg/kg; intravenous injection; single dose) suppresses tumor growth in multiple myeloma and enhances host survival in vivo. |
| Synonyms | nBT062-DM4, BT-062 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | ＜ 1.0 EU/mg |
| Target | CD138 |
| Cas No. | 1238517-16-2 |
| Storage | -20°C for 1 year | Shipping with blue ice. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Indatuximab ravtansine | purchase Indatuximab ravtansine | Indatuximab ravtansine cost | order Indatuximab ravtansine | Indatuximab ravtansine in vivo | Indatuximab ravtansine in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.